Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current $260.
Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.
Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.
The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease appeared first on Investor's Business Daily.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen (AMGN) reachead $273.41 at the closing of the latest trading day, reflecting a -0.85% change compared to its last close.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.